Salvador Martín Algarra-rekin lankidetzan egindako argitalpenak (25)

2024

  1. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes

    Endocrine-related cancer, Vol. 31, Núm. 10

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2017

  1. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

2015

  1. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

    Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236

  2. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

    Melanoma Research, Vol. 25, Núm. 6, pp. 486-495

  3. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

  4. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

    Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304

  5. Variations in molecular profile in NSCLC can be analyzed using cytological samples: Development of EGFR resistance mutations and coexistence of ALK-EML4 translocation in an EGFR-sensitive patient

    International Journal of Surgical Pathology, Vol. 23, Núm. 2, pp. 111-115

2014

  1. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  2. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients

    Clinica Chimica Acta, Vol. 429, pp. 168-174

  3. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

  4. Study of circulating MicroRNA-125b levels in serum exosomes in advanced melanoma

    Archives of Pathology and Laboratory Medicine, Vol. 138, Núm. 6, pp. 828-832

2012

  1. Immunostimulatory monoclonal antibodies for melanoma treatment

    Emerging Therapeutics for Melanoma (Future Medicine Ltd.), pp. 81-91

2011

  1. Assessment of epidermal growth factor receptor and krasmutation status in cytological stained smears of non-small celllung cancer patients: Correlation with clinical outcomes

    Oncologist, Vol. 16, Núm. 6, pp. 877-885

  2. Determinants of toxicity, patterns of failure, and outcome among adult patients with soft tissue sarcomas of the extremity and superficial trunk treated with greater than conventional doses of perioperative high-dose-rate brachytherapy and external beam radiotherapy

    International Journal of Radiation Oncology Biology Physics, Vol. 81, Núm. 4

  3. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

2007

  1. Carcinoma microcítico de pulmón

    Revista de medicina, Vol. 51, Núm. 2, pp. 7-13

  2. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  3. Small-cell lung cancer

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 7-13

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140